NO902696D0 - Ny familie av modifiserte hoeyaffinitetsantistoff for kreftbehandling. - Google Patents

Ny familie av modifiserte hoeyaffinitetsantistoff for kreftbehandling.

Info

Publication number
NO902696D0
NO902696D0 NO1990902696A NO902696A NO902696D0 NO 902696 D0 NO902696 D0 NO 902696D0 NO 1990902696 A NO1990902696 A NO 1990902696A NO 902696 A NO902696 A NO 902696A NO 902696 D0 NO902696 D0 NO 902696D0
Authority
NO
Norway
Prior art keywords
antibodies
high efficiency
cancer treatment
modified high
new family
Prior art date
Application number
NO1990902696A
Other languages
English (en)
Other versions
NO301075B1 (no
NO902696L (no
Inventor
Peter Mezes
Brian Gourlie
Mark Rixon
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of NO902696D0 publication Critical patent/NO902696D0/no
Publication of NO902696L publication Critical patent/NO902696L/no
Priority to NO19960274A priority Critical patent/NO316023B1/no
Publication of NO301075B1 publication Critical patent/NO301075B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO902696A 1988-10-19 1990-06-18 Antistoff som er selektive for TAG-72 for diagnostisk bruk, DNA-sekvens som koder for det, ekspresjonsbærer og celle som kan uttrykke det samt blanding som omfatter antistoffet NO301075B1 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO19960274A NO316023B1 (no) 1988-10-19 1996-01-23 Fremgangsmåte for fremstilling av et terapeutisk aktivt antistoff eller etterapeutisk aktivt fragment derav som er selektive for TAG-72

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25994388A 1988-10-19 1988-10-19
PCT/US1989/004402 WO1990004410A1 (en) 1988-10-19 1989-10-04 A novel family of high affinity, modified antibodies for cancer treatment

Publications (3)

Publication Number Publication Date
NO902696D0 true NO902696D0 (no) 1990-06-18
NO902696L NO902696L (no) 1990-08-16
NO301075B1 NO301075B1 (no) 1997-09-08

Family

ID=22987104

Family Applications (1)

Application Number Title Priority Date Filing Date
NO902696A NO301075B1 (no) 1988-10-19 1990-06-18 Antistoff som er selektive for TAG-72 for diagnostisk bruk, DNA-sekvens som koder for det, ekspresjonsbærer og celle som kan uttrykke det samt blanding som omfatter antistoffet

Country Status (21)

Country Link
EP (2) EP0397821A4 (no)
JP (1) JP2935520B2 (no)
KR (1) KR0161525B1 (no)
AR (1) AR242434A1 (no)
AT (1) ATE111519T1 (no)
AU (2) AU4429989A (no)
BR (1) BR8907126A (no)
CA (1) CA2000913C (no)
DE (1) DE68918217T2 (no)
DK (1) DK173089B1 (no)
ES (1) ES2059670T3 (no)
FI (1) FI103181B1 (no)
HK (1) HK162795A (no)
HU (1) HU218093B (no)
IE (1) IE64966B1 (no)
IL (1) IL92037A (no)
NO (1) NO301075B1 (no)
NZ (1) NZ231012A (no)
PT (1) PT92013B (no)
WO (1) WO1990004410A1 (no)
ZA (1) ZA897858B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5976531A (en) * 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
US6495137B1 (en) 1990-04-19 2002-12-17 The Dow Chemical Company Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0523949B1 (en) * 1991-07-15 2003-06-25 The Wellcome Foundation Limited Production of antibodies
US6025165A (en) * 1991-11-25 2000-02-15 Enzon, Inc. Methods for producing multivalent antigen-binding proteins
AU696627B2 (en) * 1991-12-13 1998-09-17 Dow Chemical Company, The Composite antibodies of human subgroup IV light chain capable of binding to TAG-72
EP0618969B1 (en) * 1991-12-13 2003-06-25 The Dow Chemical Company Composite antibodies of human subgroup iv light chain capable of binding to tag-72
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
JP3312357B2 (ja) 1992-12-11 2002-08-05 ザ ダウ ケミカル カンパニー 多価の一本鎖抗体
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
IL138021A0 (en) * 1998-02-25 2001-10-31 Dow Chemical Co High affinity humanized anti-tag-72 monoclonal antibodies
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
EP1532162B1 (en) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US73685A (en) * 1868-01-21 Improvement in ploughs
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
FR2788040B1 (fr) * 1998-12-31 2001-03-23 Airsec Sa Distributeur d'objets

Also Published As

Publication number Publication date
KR900701302A (ko) 1990-12-01
FI103181B (fi) 1999-05-14
JPH03502889A (ja) 1991-07-04
ZA897858B (en) 1991-06-26
DE68918217D1 (de) 1994-10-20
EP0365997B1 (en) 1994-09-14
HUT56878A (en) 1991-10-28
BR8907126A (pt) 1991-02-13
FI903056A0 (fi) 1990-06-18
CA2000913A1 (en) 1990-04-19
EP0397821A4 (en) 1992-03-18
IL92037A0 (en) 1990-07-12
HU896255D0 (en) 1991-09-30
AU4429989A (en) 1990-05-14
IE64966B1 (en) 1995-09-20
ATE111519T1 (de) 1994-09-15
CA2000913C (en) 1999-02-16
HU218093B (hu) 2000-05-28
WO1990004410A1 (en) 1990-05-03
NO301075B1 (no) 1997-09-08
EP0365997A2 (en) 1990-05-02
EP0397821A1 (en) 1990-11-22
HK162795A (en) 1995-10-27
PT92013B (pt) 1995-07-06
ES2059670T3 (es) 1994-11-16
DK149990A (da) 1990-08-17
JP2935520B2 (ja) 1999-08-16
EP0365997A3 (en) 1992-03-04
DE68918217T2 (de) 1995-02-09
DK173089B1 (da) 2000-01-10
IE893347L (en) 1990-04-19
NO902696L (no) 1990-08-16
NZ231012A (en) 1993-02-25
AU4354089A (en) 1990-04-26
PT92013A (pt) 1990-04-30
KR0161525B1 (ko) 1998-12-01
DK149990D0 (da) 1990-06-19
FI103181B1 (fi) 1999-05-14
AU633026B2 (en) 1993-01-21
IL92037A (en) 1998-03-10
AR242434A1 (es) 1993-03-31

Similar Documents

Publication Publication Date Title
NO902696L (no) Ny familie av modifiserte hoeyaffinitets-antistoff for kreftbehandling.
NO872589D0 (no) Noeytrale metalloendopeptidaseinhibitorer for behandling av hypertensjon.
DE68920775D1 (de) Behandlung von faserigen Materialien.
NO894929D0 (no) Verktoey for behandling av undergrunnsbroenner.
NO870770L (no) FremgangsmŸte for fremstilling av monoklonale antistoffer.
NO873325L (no) Sekresjon av heterologe proteiner av gjaer.
NO870409L (no) Fremgangsmaate for spaltning av 1-aminoindaner.
NO890235D0 (no) Fremgangsmaate til agglomerering av partikler.
NO893794D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO893143D0 (no) Fremstilling av klordioksyd.
NO881255L (no) Behandling av fluider.
NO872255D0 (no) Fremgangsmaate for dekaffinering av raakaffe.
FI843040A (fi) Anordning foer utmatning av exempelvis goedsel.
NO881365L (no) Behandling av stoev.
NO157828C (no) Behandling av treflis.
NO893796L (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO893795D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO902968D0 (no) Fremgangsmaate for behandling av boreslam.
FI906144A0 (fi) Modifiering av plasminogenaktivatorer.
NO863283D0 (no) Framgangsmaate for behandling av raa skjell.
FI885447A (fi) Anordning och foerfarande foer kalkning av vattendrag.
FI881384A0 (fi) Anordning foer rengoering av skodon.
FI883791A0 (fi) Foerfarande och anordning foer framstaellning av glasfiber.
FI883463A0 (fi) Anordning foer undervattensarbete.
NO890484L (no) Framgangsmaate for katalytisk dehydrogenering av parafiner.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees